|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...2223242526272829303132...39313932» |
- | Rituxan (rituximab) / Roche
Journal: Intestinal stenosis developed after a complete response to chemotherapy in a patient with Crohn (Pubmed Central) - Sep 20, 2024
Histological and cytometry findings led to a diagnosis of large B cell lymphoma, for which the patient received standard treatment (R-CHOP and IPI), achieving complete response...An histological analysis of the surgical piece revealed a granulomatous reaction with multinucleated foreign body-like giant cells, without evidence of malignancy (recurrence of lymphoma) nor inflammatory infiltrate suggesting CD. The patient currently remains asymptomatic with no new episodes of abdominal pain.
- | BI 764532 / Boehringer Ingelheim
Trial completion date, Combination therapy: DAREONTM-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy (clinicaltrials.gov) - Sep 20, 2024
P1, N=54, Recruiting, Sponsor: Boehringer Ingelheim
The patient currently remains asymptomatic with no new episodes of abdominal pain. Trial completion date: Dec 2025 --> Apr 2026
- | Hansizhuang (serplulimab) / Fosun Pharma
New trial: Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 20, 2024
P=N/A, N=50, Not yet recruiting, Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
- ||| ALN-BCAT / Alnylam
New P1 trial, Combination therapy, Monotherapy, Metastases: A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 20, 2024
P1, N=158, Not yet recruiting, Sponsor: Alnylam Pharmaceuticals
- || Rituxan (rituximab) / Roche
Trial completion, Trial completion date: Lenalidomide and Rituximab in Subjects with Previously Untreated Indolent Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Sep 20, 2024
P2, N=30, Completed, Sponsor: University of California, Davis
Trial completion date: Dec 2025 --> Apr 2026 Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Apr 2024
- | Opdivo (nivolumab) / BMS
New P1 trial: Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer (clinicaltrials.gov) - Sep 20, 2024
P1, N=10, Not yet recruiting, Sponsor: Abramson Cancer Center at Penn Medicine
- | Trial completion, Trial completion date, Metastases: Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov) - Sep 20, 2024
P2, N=32, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Apr 2024 Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Aug 2024
- | numidargistat (INCB001158) / Calithera
Phase classification, Combination therapy, Metastases: KEYNOTE 741: Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - Sep 20, 2024
P1, N=260, Completed, Sponsor: Incyte Corporation
Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Aug 2024 Phase classification: P1/2 --> P1
- | Imfinzi (durvalumab) / AstraZeneca
Trial primary completion date, Combination therapy: Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma (clinicaltrials.gov) - Sep 20, 2024
P1/2, N=38, Active, not recruiting, Sponsor: City of Hope Medical Center
Phase classification: P1/2 --> P1 Trial primary completion date: Jun 2025 --> Dec 2024
- ||| Enrollment open, Metastases: A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (clinicaltrials.gov) - Sep 20, 2024
P1, N=422, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2025 --> Dec 2024 Active, not recruiting --> Recruiting
- ||| Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche
Trial completion: Pembrolizumab and Reirradiation in Bevacizumab Na (clinicaltrials.gov) - Sep 20, 2024
P2, N=60, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- | Xpovio (selinexor) / Karyopharm
Trial completion date, Trial termination, Trial primary completion date, Combination therapy, IO biomarker, Metastases: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Sep 20, 2024
P1, N=221, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial completion date: Dec 2024 --> Sep 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Sep 2024; Administratively Complete
- ||| pegenzileukin (SAR444245) / Sanofi
Enrollment closed, Combination therapy, Metastases: HAMMER: A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) (clinicaltrials.gov) - Sep 20, 2024
P1/2, N=250, Active, not recruiting, Sponsor: Synthorx, Inc, a Sanofi company
Trial completion date: Dec 2024 --> Sep 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Sep 2024; Administratively Complete Recruiting --> Active, not recruiting
- || Tecvayli (teclistamab-cqyv) / Genmab, J&J
Enrollment closed: MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 20, 2024
P1, N=302, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| JAB-3068 / Jacobio Pharma
Trial completion, Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: JAB-3068 Activity in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Sep 20, 2024
P1/2, N=12, Completed, Sponsor: Jacobio Pharmaceuticals Co., Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed | Phase classification: P1b/2a --> P1/2 | N=118 --> 12 | Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Feb 2022 --> Dec 2023
- ||| Cerebraca Wafer ((Z)-n-butylidenephthalide/polymer wafer) / Everfront Biotech
Trial completion, Enrollment change, Trial completion date: A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma (clinicaltrials.gov) - Sep 20, 2024
P1/2, N=22, Completed, Sponsor: Everfront Biotech Co., Ltd.
Recruiting --> Completed | Phase classification: P1b/2a --> P1/2 | N=118 --> 12 | Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Feb 2022 --> Dec 2023 Active, not recruiting --> Completed | N=36 --> 22 | Trial completion date: Dec 2024 --> Sep 2024
- ||| Ibrance (palbociclib) / Pfizer, Xenical (orlistat) / Roche, GSK
Journal, Adverse events: Exploring the top 30 drugs associated with drug-induced constipation based on the FDA adverse event reporting system. (Pubmed Central) - Sep 20, 2024
The drug with the highest ranking was lenalidomide (7,730 cases, 4.55%), with the most prevalent drug class being antineoplastic and immunomodulating agents...However, four drugs (orlistat, nintedanib, palbociclib, and dimethyl fumarate) presented an unexpected risk of constipation. Ranked by signal values, sevelamer carbonate emerged as the drug with the strongest risk signal [reporting odds ratio (95% CI): 115.51 (110.14, 121.15); PRR (?2): 83.78 (191,709.73); EBGM (EB05): 82.63 (79.4); IC (IC025): 6.37 (4.70)]...The median TTO for orlistat was 3
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, HEOR: Recurrent high grade serous endometrial cancer with brain metastases: Immunotherapy confers improved quality of life and survival. (Pubmed Central) - Sep 20, 2024
Ranked by signal values, sevelamer carbonate emerged as the drug with the strongest risk signal [reporting odds ratio (95% CI): 115.51 (110.14, 121.15); PRR (?2): 83.78 (191,709.73); EBGM (EB05): 82.63 (79.4); IC (IC025): 6.37 (4.70)]...The median TTO for orlistat was 3 No abstract available
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Camrelizumab combined with chemotherapy for stage IV pulmonary sarcomatoid cancer with pancreatic metastases. (Pubmed Central) - Sep 20, 2024
Camrelizumab and chemotherapy were administered, and the metastasis disappeared. Immunotherapy combined with platinum-based chemotherapy is effective in treating PSC with pancreatic metastases.
- | Darzalex (daratumumab) / J&J
Journal: Periorbital purpura can be the only initial symptom of primary light chain amyloidosis: A case report. (Pubmed Central) - Sep 20, 2024
Immunotherapy combined with platinum-based chemotherapy is effective in treating PSC with pancreatic metastases. Periorbital purpura can be the only initial symptom of primary light chain amyloidosis; we should pay attention to the cases where the initial clinical symptoms are only periorbital purpura.
- | Preclinical, Journal: Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation. (Pubmed Central) - Sep 20, 2024
Our investigation revealed that the pathogenic mechanism underlying IH might be closely associated with the PI3K/AKT/MTOR, RAS/MAPK, and CGMP/PKG signaling pathways. Furthermore, we identified twelve molecular-targeting agents among the predicted drugs that show promise as therapeutic candidates for IH.
- || nazartinib (EGF816) / Novartis
Trial completion date, Trial primary completion date, Combination therapy: Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (clinicaltrials.gov) - Sep 20, 2024
P1, N=105, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Furthermore, we identified twelve molecular-targeting agents among the predicted drugs that show promise as therapeutic candidates for IH. Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Dec 2024 --> Apr 2025
- || Carvykti (ciltacabtagene autoleucel) / J&J, Talvey (talquetamab-tgvs) / J&J
Enrollment open: MonumenTAL-8: A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (clinicaltrials.gov) - Sep 20, 2024
P2, N=30, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Dec 2024 --> Apr 2025 Not yet recruiting --> Recruiting
- || Imdelltra (tarlatamab-dlle) / Amgen
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: DeLLphi-303: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov) - Sep 20, 2024
P1, N=184, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=340 --> 184 | Trial completion date: Jun 2029 --> Aug 2028 | Trial primary completion date: Jun 2029 --> Aug 2028
- | Rituxan (rituximab) / Roche
New trial: Intervention effect of Yi Qi Wen Yang decoction on cardiac damage of anthracycline chemotherapeutic drugs (EUDRACT) - Sep 20, 2024
P=N/A, N=80, Not yet recruiting, Sponsor: Jiangsu Provincial Hospital of Chinese Medicine; Jiangsu Provincial Hospital of Chinese Medicine
- | topotecan / Generic mfg.
New trial: A Prospective, Single-Arm, Exploratory Clinical Study of Anti-PD-1 Monoclonal Antibody Combined with Topotecan Capsules for Consolidation of Limited Stage Small Cell Lung Cancer That Has Not Progressed After Concurrent or Sequential Chemoradiotherapy (EUDRACT) - Sep 20, 2024
P=N/A, N=46, Recruiting, Sponsor: Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital
- | Kaitanni (cadonilimab) / Akesobio
New trial, Metastases: A Phase II Clinical Study of HIPEC Combined with Cadonilimab and SOX Chemotherapy for Conversion Therapy in Patients with Advanced Gastric Cancer with Peritoneal Metastasis (EUDRACT) - Sep 20, 2024
P=N/A, N=46, Recruiting, Sponsor: Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New trial: A single-center, randomized, controlled clinical study of Herombopag for the treatment of thrombocytopenia before liver resection (EUDRACT) - Sep 20, 2024
P=N/A, N=96, Recruiting, Sponsor: Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
- | Anruixi (zuberitamab) / Zhejiang Hisun
New trial, Real-world evidence, Real-world: LYMPHOPE: A real-world study of Zuberitamab Injection in Chinese patients with diffuse large B-cell lymphoma (EUDRACT) - Sep 20, 2024
P=N/A, N=500, Not yet recruiting, Sponsor: HARBIN THE FIRST HOSPITAL; HARBIN THE FIRST HOSPITAL
- | Kaitanni (cadonilimab) / Akesobio
New trial, Metastases: Cadonilimab in neoadjuvant chemotherapy and maintenance therapy for newly diagnosed, high-risk, locally advanced cervical cancer :a multi-center, prospective, single-arm study (EUDRACT) - Sep 20, 2024
P=N/A, N=20, Not yet recruiting, Sponsor: Hubei Cancer Hospital; Hubei Cancer Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Camrelizumab plus apatinib as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after radical resection or ablation: a single-arm, single-center, exploratory trial (EUDRACT) - Sep 20, 2024
P=N/A, N=38, Not yet recruiting, Sponsor: Zhujiang Hospital of Southern Medical University; Zhujiang Hospital of Southern Medical University
- | Epidaza (chidamide) / Chipscreen, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
New trial, Metastases: Camrelizumab and Chidamide together with an S-1-based chemotherapy regimen as second-line therapy in advanced and metastatic biliary tract cancer: A single-arm, exploratory, phase 2 trial. (EUDRACT) - Sep 20, 2024
P=N/A, N=30, Recruiting, Sponsor: First affiliated hospital of Soochow university; First affiliated hospital of Soochow university
- | Opdivo (nivolumab) / BMS
New trial, Metastases: Retrospective Evaluation of Nivolumab in First-line unresectable advanced or metastatic Gastric Cancer (GC) and Gastroesophageal Junction Cancer (GEJC) : A Non-interventional Study in China (EUDRACT) - Sep 20, 2024
P=N/A, N=260, Not yet recruiting, Sponsor: Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College ,Huazhong University o
- | Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
New trial: Study on the efficacy, safety, new evaluation methods and application of molecular prognostic models of MEDZ-R regimen in the treatment of primary central nervous system large B-cell lymphoma under the guidance of precision medicine (EUDRACT) - Sep 20, 2024
P=N/A, N=43, Recruiting, Sponsor: West China Hospital, Sichuan University; West China Hospital, Sichuan University
- | BNT113 / BioNTech
New trial: Observational study on the correlation between the immune response of patients' peripheral blood stimulated by therapeutic HPV mRNA vaccine in vitro and the pathological results and clinical prognosis of patients (EUDRACT) - Sep 20, 2024
P=N/A, N=150, Not yet recruiting, Sponsor: Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medi
- | Anpingxi (ripertamab) / Sinocelltech
New trial, Real-world evidence, Real-world: Efficacy and Safety of Ripertamab With or Without Other Drugs in B-cell Non-Hodgkin's Lymphomas (EUDRACT) - Sep 20, 2024
P=N/A, N=400, Recruiting, Sponsor: Institute of Hematology and Oncology, Harbin The First Hospital; Institute of Hematology and Oncology, Harbin The First Hospital
- | Gazyva (obinutuzumab) / Roche, Biogen
Biomarker, New trial: Prognostic factors of the efficacy of Obinutuzumab in B cell lymphoma: a retrospective single-center clinical study (EUDRACT) - Sep 20, 2024
P=N/A, N=113, Recruiting, Sponsor: Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P4 trial, Real-world evidence, Real-world, Metastases: A prospective, real-world clinical study of camrelizumab combined with weak chemotherapy and first-line treatment of driver gene-negative advanced NSCLC (EUDRACT) - Sep 20, 2024
P4, N=100, Not yet recruiting, Sponsor: Shandong Provincial Public Health Clinical Center; Shandong Provincial Public Health Clinical Center
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P4 trial, Metastases: A Single-Arm, Single-Center, Exploratory Clinical Study of Apatinib Mesylate Combined with Camrelizumab and Capox Chemotherapy as Neoadjuvant Therapy for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma (EUDRACT) - Sep 20, 2024
P4, N=41, Not yet recruiting, Sponsor: Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College
- | Tyvyt (sintilimab) / Eli Lilly
New P4 trial, IO biomarker, Metastases: Efficacy and safety of intrapleural administration of sintilimab in advanced non-small cell lung cancer patients with malignant pleural effusion: a prospective multi-center study (EUDRACT) - Sep 20, 2024
P4, N=17, Completed, Sponsor: General Hospital Of Eastern Theater Command; General Hospital Of Eastern Theater Command
- | Cosela (trilaciclib) / G1 Therap
New P4 trial: A Single-Arm, Observational Study to Assess the Efficacy and Safety of Trilaciclib in Extensive Stage Small Cell Lung Cancer Patients with Chemotherapy Induced Grade 3/4 Myelosuppression Following Prior Chemotherapy (EUDRACT) - Sep 20, 2024
P4, N=20, Recruiting, Sponsor: Tangdu Hospital, Fourth Military Medical University; Tangdu Hospital, Fourth Military Medical University
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
New P4 trial, Metastases: A single arm, prospective phase II clinical study to evaluate the efficacy and safety of retinoic acid capsules combined with toripalimab in the treatment of advanced unresectable or metastatic melanoma (EUDRACT) - Sep 20, 2024
P4, N=41, Not yet recruiting, Sponsor: Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P4 trial, Real-world evidence, Real-world, Metastases: A real-world study of thalidomide for the prevention of adverse reactions associated with carilizumab-induced treatment of advanced non-small cell lung cancer (EUDRACT) - Sep 20, 2024
P4, N=100, Not yet recruiting, Sponsor: Huai'an First People's Hospital; Huai'an First People's Hospital
- | Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
New P4 trial: Clinical Study of Inebilizumab Combined with Steroids for the Treatment of Neuromyelitis Optica Spectrum Disorder (EUDRACT) - Sep 20, 2024
P4, N=128, Recruiting, Sponsor: West China Hospital,Sichuan University; West China Hospital,Sichuan University
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial, Metastases: Adebrelimab plus chemotherapy as first-line treatment in advanced first-line non-small cell lung cancer:a single arm ,phase 2 trial. (EUDRACT) - Sep 20, 2024
P4, N=42, Not yet recruiting, Sponsor: Taihe hospital,Affiliated hospital of hubei university of medicine; Taihe hospital
- | AiTan (rivoceranib) / HLB Bio Group, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial: Exploratory study on the combination of Adebrelimab and Apatinib in the treatment of PD-1 inhibitor induced liver cancer (EUDRACT) - Sep 20, 2024
P4, N=114, Not yet recruiting, Sponsor: Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial, Metastases: Adebrelimab (PD-L1) combined with gemcitabine and cisplatin (GP regimen) for unresectable advanced biliary tract cancer (EUDRACT) - Sep 20, 2024
P4, N=144, Not yet recruiting, Sponsor: Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital Affiliated to Shandong First Medical Univer
- | Arzerra (ofatumumab) / Novartis, Genmab
New P4 trial: Ofatumumab for the treatment of optic neuritis associated with neuromyelitis optica spectrum disorder (EUDRACT) - Sep 20, 2024
P4, N=10, Recruiting, Sponsor: Chinese PLA General Hospital & Chinese PLA Medical School; Chinese PLA General Hospital & Chinese PLA Medical School
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Cosela (trilaciclib) / G1 Therap
New P3 trial, Metastases: A Multicenter, Phase III, Randomized Controlled Trial on the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib in Untreated Unresectable and Metastatic Urothelial Carcinoma (EUDRACT) - Sep 20, 2024
P3, N=192, Not yet recruiting, Sponsor: Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- | Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial, Combination therapy, Metastases: A Phase III, Randomized, Double-blinded, Multicenter Study of Cadonilimab (AK104) + Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (EUDRACT) - Sep 20, 2024
P3, N=469, Recruiting, Sponsor: Zhongda Hospital Southeast University; Zhongda Hospital Southeast University